On ECHEMI
Home > Drugs > Lingbao City Yuxi Pharmaceutical Co., Ltd.
Lingbao City Yuxi Pharmaceutical Co., Ltd.
  • Founded in:

    1999-05-19
  • Country:

    China China
  • Address:

    West section of Station Road, Lingbao City
  • Tax NO.:

    914112827066645112
  • Registered Funds:

    6.53 million yuan
  • Website:

  • Email:

Related Drugs
Calcium lactate tablets
Each tablet of this product contains 0.25g of calcium lactate (equivalent to 32.5mg of calcium), the main ingredient. The auxiliary materials are starch and magnesium stearate.
Name Description Content CAS NO. Registered Holders
Calcium lactate

Participates in bone formation and reconstruction of bone tissue after fracture, as well as muscle contraction, nerve transmission, coagulation mechanism and reduces capillary permeability, etc.

More

Participates in bone formation and reconstruction of bone tissue after fracture, as well as muscle contraction, nerve transmission, coagulation mechanism and reduces capillary permeability, etc.

0.25g 814-80-2 10
Starch

This product is involved in the formation of bones and the reconstruction of bone tissue after fracture, as well as muscle contraction, nerve transmission, coagulation mechanism and reducing the permeability of capillaries.

More

This product is involved in the formation of bones and the reconstruction of bone tissue after fracture, as well as muscle contraction, nerve transmission, coagulation mechanism and reducing the permeability of capillaries.

9005-25-8 77
Magnesium stearate

This product is involved in the formation of bones and the reconstruction of bone tissue after fracture, as well as muscle contraction, nerve transmission, coagulation mechanism and reducing the permeability of capillaries.

More

This product is involved in the formation of bones and the reconstruction of bone tissue after fracture, as well as muscle contraction, nerve transmission, coagulation mechanism and reducing the permeability of capillaries.

557-04-0 61
Calcium lactate
Name Description Content CAS NO. Registered Holders
Calcium lactate

No specific pharmacological effects mentioned

More

No specific pharmacological effects mentioned

814-80-2 10
Cetirizine Hydrochloride Capsules
The main ingredient of this product is cetirizine hydrochloride, and its chemical name is (±)-2-[2-[4-[(4-chlorophenyl)benzyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride.
Name Description Content CAS NO. Registered Holders
Cetirizine dihydrochloride

Selective histamine H1 receptor antagonist, no obvious anticholinergic and anti-5-hydroxytryptamine effect, not easy to pass through the blood-cerebrospinal fluid barrier to act on the central H1 receptor, clinical use of central inhibition is relatively mild

More

Selective histamine H1 receptor antagonist, no obvious anticholinergic and anti-5-hydroxytryptamine effect, not easy to pass through the blood-cerebrospinal fluid barrier to act on the central H1 receptor, clinical use of central inhibition is relatively mild

83881-52-1 54
Berberine Trimethoprim Tablets
This product is a compound preparation, and its components are: each tablet contains 100 mg of berberine hydrochloride and 50 mg of trimethoprim.
Name Description Content CAS NO. Registered Holders
Berberine hydrochloride

It has an inhibitory effect on a variety of Gram-positive and Gram-negative bacteria in vitro, and has a stronger inhibitory effect on hemolytic Streptococcus, Staphylococcus aureus, Vibrio cholerae, Neisseria meningitidis, Shigella, Salmonella typhi, Corynebacterium diphtheriae, etc. It also has a certain inhibitory effect on amoeba.

More

It has an inhibitory effect on a variety of Gram-positive and Gram-negative bacteria in vitro, and has a stronger inhibitory effect on hemolytic Streptococcus, Staphylococcus aureus, Vibrio cholerae, Neisseria meningitidis, Shigella, Salmonella typhi, Corynebacterium diphtheriae, etc. It also has a certain inhibitory effect on amoeba.

100mg 633-65-8 46
Trimethoprim

It mainly interferes with bacterial folate metabolism, selectively inhibits dihydrofolate reductase, and prevents nucleic acid synthesis.

More

It mainly interferes with bacterial folate metabolism, selectively inhibits dihydrofolate reductase, and prevents nucleic acid synthesis.

50mg 738-70-5 44
Nalmefene Hydrochloride Injection
The main ingredient of this product is nalmefene hydrochloride, its chemical name is: 17-cyclopropylmethyl-4,5α-epoxy-6-methylenemorphinan-3,14-diol hydrochloride, and its structural formula is: Molecular formula: C21H25NO3·HCl Molecular weight: 375.9 Excipients are sodium chloride and water for injection.
Name Description Content CAS NO. Registered Holders
Nalmefene hydrochloride

Nalmefene is an opioid receptor antagonist that can inhibit or reverse the respiratory depression, sedation, and hypotension effects of opioid drugs. Pharmacodynamic studies have shown that the duration of action of nalmefene is longer than that of naloxone at a complete reversal dose. Nalmefene has no opioid agonist activity and does not produce respiratory depression, hallucinogenic effects, or mydriasis. No pharmacological effects were observed when nalmefene was administered in the absence of an opioid agonist. No tolerance, physical dependence, or abuse liability of nalmefene was observed in the study. In opioid-dependent individuals, nalmefene can produce acute withdrawal symptoms.

More

Nalmefene is an opioid receptor antagonist that can inhibit or reverse the respiratory depression, sedation, and hypotension effects of opioid drugs. Pharmacodynamic studies have shown that the duration of action of nalmefene is longer than that of naloxone at a complete reversal dose. Nalmefene has no opioid agonist activity and does not produce respiratory depression, hallucinogenic effects, or mydriasis. No pharmacological effects were observed when nalmefene was administered in the absence of an opioid agonist. No tolerance, physical dependence, or abuse liability of nalmefene was observed in the study. In opioid-dependent individuals, nalmefene can produce acute withdrawal symptoms.

58895-64-0 19
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.